This is a working overview of GLP-1 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-14. Anything still debated is marked as such rather than presented as settled.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
However, in Dano v Jobcenter Leipzig, the Court of Justice held that the German government was entitled to deny child support to a Romanian mother who had lived in Germany for three years, but had never worked. Because she lived in Germany for over 3 months, but under five years, she had to show evidence of "sufficient resources", since the Court reasoned the right to equal treatment in article 24 within that time depended on lawful residence under article 7.
Among other things, the parathyroid hormone causes calcium and phosphate to be released from the bones, which ultimately leads to renal bone disorders and calcification of the kidneys, skin, heart and blood vessels. In the kidneys, this calcification contributes to further destruction of the kidney tissue. The reduced responsiveness of the parathyroid cells to calcium disrupts the negative feedback of parathyroid hormone secretion, so that parathyroid hormone continues to be secreted despite the increase in calcium levels. As less phosphate reaches the renal tubules due to the reduced filtration rate, the inhibitory effect of parathyroid hormone on reabsorption in the main body has only a minor effect on the blood phosphate level. The loss of nephrons and the associated decrease in the number of sodium ion channels leads to a decrease in the concentration gradient in the kidney. However, this is the driving force for water reabsorption in the mid-piece and—in the presence of ADH—also in the collecting ducts. The result is a loss of water via the urine and thus drying out of the body, which is exacerbated by the loss of fluid during vomiting. One consequence of the kidneys' reduced ability to excrete hydrogen ions, phosphate and sulphate and the excessive loss of bicarbonate is the metabolic acidification of the blood (metabolic acidosis). Metabolic acidosis occurs in 80% of cats with chronic kidney disease.
=== Period 1: "Classical" early style (circa 300–400 CE) === The earliest paintings at Kizil belong to a "Classical" stage. Their style is very elegant and "painterly", with sophisticated shading of the bodies to express sculptural volume. The lines are refined and subtle, the colors blend softly. This style is also characteristically Indian, and may be related to Gandhara or Kashmir. This early style is exemplified by the Cave of the Hippocampi (Cave 118), and may form a distinctive school. This contrasts with the style of the following stage, as seen in the panels in the cella of the Cave of the Statues, such as the "Cowherd Nanda", which is much bolder, using intense colors (but still browns, greens and oranges only), thicker lines and simpler patterns.
The species previously thought to be AtO2− has since been determined to be AtO(OH)2−, a hydrolysis product of AtO+ (another such hydrolysis product being AtOOH). The well characterized AtO3− anion can be obtained by, for example, the oxidation of astatine with potassium hypochlorite in a solution of potassium hydroxide. Preparation of lanthanum triastatate La(AtO3)3, following the oxidation of astatine by a hot Na2S2O8 solution, has been reported. Further oxidation of AtO3−, such as by xenon difluoride (in a hot alkaline solution) or periodate (in a neutral or alkaline solution), yields the perastatate ion AtO4−; this is only stable in neutral or alkaline solutions. Astatine is also thought to be capable of forming cations in salts with oxyanions such as iodate or dichromate; this is based on the observation that, in acidic solutions, monovalent or intermediate positive states of astatine coprecipitate with the insoluble salts of metal cations such as silver(I) iodate or thallium(I) dichromate. Astatine may form bonds to the other chalcogens; these include S7At+ and At(CSN)2− with sulfur, a coordination selenourea compound with selenium, and an astatine–tellurium colloid with tellurium.
To develop organisms with novel or enhanced characteristics, this emerging field of study combines biology, engineering, and related disciplines' knowledge and techniques to design chemically synthesized DNA. Biomolecular engineering includes approaches that aim to create a toolkit of functional units that can be introduced to present new technological functions in living cells. Genetic engineering includes approaches to construct synthetic chromosomes or minimal organisms like Mycoplasma laboratorium. Biomolecular design refers to the general idea of de novo design and additive combination of biomolecular components. Each of these approaches shares a similar task: to develop a more synthetic entity at a higher level of complexity by inventively manipulating a simpler part at the preceding level. Optimizing these exogenous pathways in unnatural systems takes iterative fine-tuning of the individual biomolecular components to select the highest concentrations of the desired product. On the other hand, "re-writers" are synthetic biologists interested in testing the irreducibility of biological systems. Due to the complexity of natural biological systems, it would be simpler to rebuild the natural systems of interest from the ground up; to provide engineered surrogates that are easier to comprehend, control and manipulate. Re-writers draw inspiration from refactoring, a process sometimes used to improve computer software.
Sources: en.wikipedia.org
In 1982, Hafez al-Assad responded to an insurrection led by the Muslim Brotherhood in the city of Hama by sending paramilitary forces that indiscriminately killed between 40,000 and 55,000 civilians including children, women, and the elderly during the Hama massacre. State-violence perpetrated by Assad's reign have targeted women extensively, subjecting them to discrimination and gender-based violence. Between 1980 and 2000, more than 17,000 Syrian civilians were subjected to forced disappearance from the Ba'athist regime. During Baathist occupation of Lebanon, numerous Lebanese, Palestinian and other Arab civilians went missing. More than 35 torture techniques were reported to be employed in Syrian prisons and military detention centres during this time. A 1983 report published by Amnesty International revealed that Assad regime routinely committed mass-executions of alleged dissidents and engaged in the extensive torture of prisoners of conscience. Various torture methods in Syrian prisons include electrocutions, immolation, sexual violence, castration, etc. In 2000, Bashar al-Assad inherited the totalitarian system of Ba'athist Syria following the death of his father. His regime was characterized by even more systemic violence and repression than that of Hafez al-Assad. This has been widely attributed to Bashar's inexperience in security and political affairs, in addition to personal insecurities regarding the survival of his family regime.
== Effectors == Each Rho protein affects numerous proteins downstream, all of which having roles in various cell processes. Over 60 targets of the three common Rho GTPases have been found. Two molecules that directly stimulate actin polymerization are the Arp2/3 proteins and the Diaphanous-related formins.
Third-hand smoke (THS) is contamination by tobacco smoke that lingers following the extinguishing of a cigarette, cigar, or other combustible tobacco product. First-hand smoke refers to the smoke inhaled by the person who smokes. Passive smoke, or second-hand smoke, is a mixture of exhaled smoke and other substances leaving the smoldering end of the cigarette that enters the atmosphere and can be inhaled by others. Third-hand smoke or "THS" is a neologism coined by a research team from the Dana–Farber/Harvard Cancer Center, where "third-hand" is a reference to the smoking residue on surfaces after "passive smoke" has cleared out. These residual compounds can accumulate on furniture, clothing and dust, where they may persist for long periods even after ventilation or standard cleaning. Humans may subsequently be exposed to THS through inhalation, skin contact, or ingestion of contaminated particles and dust. Infants and young children are considered particularly vulnerable because they frequently crawl on contaminated surfaces, place their hands and objects in their mouths, and have developing systems. Research has associated THS exposure with respiratory problems, asthma, DNA damage, inflammatory responses, impaired wound healing, and potential developmental effects, although many long-term effects in humans remain under investigation. Studies have also shown that tobacco-specific carcinogens such as NNK can persist in indoor environments and on fabrics long after smoking has ceased.
Around 130,000 civil servants belonging to the PCS union vote to strike on 28 April in a dispute with the UK government over pay and conditions. HM Treasury scraps plans for the Royal Mint to produce a government-backed NFT that could be traded on international markets. 28 March Humza Yousaf is confirmed as Scotland's new First Minister by a vote in the Scottish Parliament. Former Labour leader Jeremy Corbyn is banned from standing as a candidate for the party at the 2024 general election after the party's National Executive Committee votes 22–12 in favour of a motion blocking his candidacy. 29 March Charles III begins a state visit to Germany, his first official overseas trip as monarch. The UK government introduces the Victims and Prisoners Bill into the House of Commons, which will give ministers the power to veto the release of some prisoners, and restrict marriage in prison for those serving whole life terms. Immigration Minister Robert Jenrick confirms the government's intention to utilise three locations, including two former military bases, to house migrants arriving into the UK as asylum seekers. The plans are an attempt by the government to save on hotel expenses. Humza Yousaf is sworn in as Scotland's First Minister at Edinburgh's Court of Session and begins naming his cabinet. 30 March The government publishes its latest net zero strategy for the period to 2050, following a High Court ruling that its earlier plans were insufficient to meet climate targets. High-profile inmate Charles Bronson loses his latest bid for freedom.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.